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Pulmonary tumours can be classified as either small cell lung
carcinomas (SCLCs) or non-small cell lung carcinomas
(NSCLCs). About 110 000 lung cancer patients in the United
States per year were killed by NSCLCs, which represent approx-
imately 75% of all lung tumours (Minna et al. 1989) including
large cell carcinomas, squamous cell carcinomas and bronchiolo-
alveolar adenocarcinomas (synonyms: adenocarcinoma, alveolar
cell carcinoma). It is currently estimated that 30–40% of all human
lung tumours are adenocarcinomas derived from either alveolar
type II pneumocytes (AT-II cells), Clara cells of the bronchiolar
epithelium or from mucin-producing cells (Tuveson and Jacks,
1999). AT-II cells and Clara cells secrete pulmonary surfactant, a
complex mixture of phospholipids and surfactant proteins (SP)
(Weaver and Whitsett, 1991). The function of the 4 known surfact-
ant proteins SP-A, SP-B, SP-C and SP-D is to contribute to the
reduction of surface tension in the lung and to facilitate gas
exchange. The expression of SP-C is restricted to AT-II cells
whereas all other surfactant proteins are secreted by both AT-II and
Clara cells (reviewed in Weaver and Whitsett, 1991; Korfhagen 
et al, 1992). Therefore, the promoter regions of surfactant protein
genes are appropriate candidates for use in the construction of lung
specific gene constructs. 
Several proto-oncogenes, including c-myc and the transforming
growth factor a (TGFa) as well as its homologue, epidermal
growth factor (EGF), are frequently found to be overexpressed in
human pulmonary carcinoids and adenocarcinomas (Battista 
et al, 1993; Broers et al, 1993; Lorenz et al, 1994; Moody, 
1996), suggesting that they may be directly involved in lung carci-
noma formation. c-myc is a member of a group of regulatory
proteins which are involved in controlling cell cycle entry,
progression and differentiation (reviewed in Facchini and Penn,
1998). 
The EGF family includes EGF, TGFa and heparin-binding
EGF. Both EGF and TGFa bind to and activate the EGF-receptor
(EGFR) (Yeh and Yeh, 1989). Bronchiolo-alveolar adenocarcin-
omas often show constitutive overexpression of EGFR as well
as of TGFa, which indicates that the resulting autocrine loop
promotes loss of cell cycle control (Tateishi et al, 1990). The 
oncogenic potential of these growth factors is supported by the
observation that overexpression of TGFa or EGF in the liver of
different transgenic mouse strains cause hepatocellular carcinomas
(Sandgren et al, 1993; Tönjes et al, 1995). 
In this work we used the AT-II cell specific SP-C promoter to
generate transgenic mouse lines constitutively overexpressing the
oncogene c-myc and a secretable form of EGF (IgEGF) (Tönjes 
et al, 1995) in the lung. Transgenics expressing c-myc developed
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Summary Transgenic mouse models were established to study tumorigenesis of bronchiolo-alveolar adenocarcinomas derived from alveolar
type II pneumocytes (AT-II cells). Transgenic lines expressing the murine oncogene c-myc under the control of the lung-specific surfactant
protein C promoter developed multifocal bronchiolo-alveolar hyperplasias, adenomas and carcinomas respectively, whereas transgenic lines
expressing a secretable form of the epidermal growth factor (IgEGF), a structural and functional homologue of transforming growth factor a
(TGFa), developed hyperplasias of the alveolar epithelium. Since the oncogenes c-myc and TGFa are frequently overexpressed in human
lung bronchiolo-alveolar adenocarcinomas, these mouse lines are useful as models for human lung bronchiolo-alveolar adenocarcinomas.
The average life expectancies of hemizygous and homozygous c-myc transgenics were 14.25 months and 9.2 months, respectively,
suggesting that a dosage effect of c-myc caused an accelerated bronchiolo-alveolar adenocarcinoma formation. First analyses of 
double transgenics, hemizygous for both c-myc and IgEGF, show that these mice develop bronchiolo-alveolar adenocarcinomas at the
average age of 9 months, indicating that these oncogenes cooperate during the lung cancer formation. Our results demonstrate that 
c-myc and EGF are directly involved and cooperate with one another during formation of bronchiolo-alveolar adenocarcinomas in the lung. 
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ively, those expressing IgEGF developed multifocal alveolar
hyperplasias. Cooperation in lung tumour formation of both trans-
genes was demonstrated in IgEGF/myc double transgenic mouse
lines. The established transgenics will provide useful animal
models to test targeted gene therapy protocols, in which the
expression of potentially cytotoxic gene products can be targeted
to cancer cells by the SP-C promoter. 
MATERIALS AND METHODS 
Cloning procedures and production of transgenic
mouse lines 
The ApaI-HindIII mouse c-myc DNA fragment from the plasmid
pTG2948 (Dalemans et al, 1990) was subcloned into the corres-
ponding restriction sites in pBSKS II (+/–) (Stratagene). ApaI was
converted into a SalI restriction site. The 2.7 kb SalI/EcoRI c-myc
DNA fragment was ligated to the SalI/EcoRI site of the vector
pUC18/3.7SP-C downstream of the human SP-C promoter 
5¢-flanking region (Wikenheiser et al, 1992). The BamHI site of
the BamHI–SalI IgEGF fragment (nucleotides 0 to 360, including
the Ig signal sequence and a synthetic EGF gene) derived from the
plasmid alb-DS4 (Tönjes et al, 1995) was converted to a SalI
restriction site. The new IgEGF SalI fragment was cloned into the
SalI restriction site 3¢ of the promoter of the human SP-C gene of
pUC18/3.7SP-C. Both gene constructs were cleaved with NdeI
and  NotI and the fusion gene fragments were purified by the
Qiagen gel extraction kit and microinjected into male pronuclei of
fertilized oocytes from hybrid CD2/F1 (DBA/2 ´ Balb/C) mice
(Hogan et al, 1994). Viable oocytes were transferred into the
oviduct of pseudopregnant CD2F1 recipient mice. Transgenic
founder mice were mated with CD2F1 for propagation as hemi-
zygous transgenics. 
Southern and Northern analysis 
Transgenic mouse lines were identified by Southern analysis of
DNA extracted from biopsied mouse tails (Hogan et al, 1994).
Restricted DNA was separated through 0.8% agarose and trans-
ferred to nylon membrane (Amersham Life Sciences) according to
standard protocols. Hybridization was performed in Church buffer
(0.25 M NaHPO4, 7.0% SDS, 10 mM EDTA, pH 7.2) at 65˚C with
the randomly labelled transgene. 
Total RNA from various tissues was isolated by the Qiagen
RNA extraction kit after homogenization using a Polytron homo-
genizer and blotted according to standard protocols. 
Histopathology 
Tissues were fixed in 4% paraformaldehyde in PBS for approx-
imately 20 h, dehydrated and embedded in paraffin (Roti®-Plast,
Roth). Tissue sections were stained with haematoxylin & eosin
according to standard protocols. The mouse tumours were classi-
fied according to the International Agency for Research on Cancer
(IARC) – WHO (2000). 
Reverse slot blot hybridization 
To analyse gene expression in lung adenocarcinomas by reverse
slot blot hybridization, 6 micrograms of each recombinant 
cDNA clone were blotted onto nylon-reinforced nitrocellulose
(Schleicher & Schuell). Total RNA was isolated from different lung
tissues using the Qiagen RNA easy kit. Synthesis and labelling of
single strand cDNA was performed as follows: 25–50 mg total
RNA were dissolved in 17 ml H2O and incubated with 5 ml oligo
(dT)12–18 bp (0.5 mg ml–1) at 70˚C for 10 min. 1.5 ml RNasin
(10 U ml–1), 7.5 ml dNTP-mix (ATP, TTP and GTP each, 5 mM), 3
ml dCTP (0.27 mM), 15 ml 5 ´ reverse transcriptase reaction buffer,
7.5 ml 0.1 M DTT, 15 ml  a-[32P]-dCTP and 3.75 ml Superscript
reverse transcriptase (200 U ml–1) (Life Technologies) was added
and incubated at 42˚C for 1 h. Free nucleotides were removed with
Micro Bio-Spin 6 Chromatography Columns (BioRad).
RNA/cDNA hybrids were denatured with one volume of 0.3 N
NaOH, 30 mM EDTA and boiled for 5 min, chilled on ice and
neutralized with 0.5 volume of 1M Tris-CL, pH 8. Hybridization of
slot blot nitrocellulose filters was performed in Church buffer for
24 h at 65˚C. After washing under stringent conditions (0.1% SDS;
0.1  ´ SSC; 65˚C) for at least 30 min, autoradiography was
performed with Kodak XOmat AR X-ray film. 
The following c-DNA-probes were used: actin, c-DNA/murine
b actin; control plasmid, pBR322; SP-A, c-DNA/murine SP-A;
SP-B, c-DNA/murine SP-B; SP-C, c-DNA/murine SP-C; cycD1,
c-DNA/human cyclin DI; cdc2, c-DNA/human cyclin dependent
kinase; c-jun, c-DNA/ murine transcription factor c-jun. 
RESULTS 
Generation of transgenic mouse lines and their
phenotypes 
The gene constructs SP-C/myc and SP-C/IgEGF (Figure 1A, B)
consisted of the murine c-myc gene and a secretable form of EGF
(IgEGF), whose expression were controlled by the human SP-C
promoter. One SP-C/IgEGF and 5 SP-C/myc founder mice were
identified by the generation of diagnostic fragments upon res-
triction enzyme digestion of mouse tail DNA and subsequent
Southern analysis as shown representative for SPC/myc transgenic
mice in Figure 3. Transgenic mouse lines were established from
the SP-C/IgEGF and two SP-C/myc transgenic founder mice. All
other founder mice were not germ line transgenic and did not
transfer the transgene to their descendants. 2 of the SP-C/myc
founder mice showed hyperplasias in the lung alveolar epithelium
(not shown). In contrast, the founder SP-C/myc 3.2 as well as all
established transgenic mouse lines, e.g SP-C/myc 8.2 and 13.0,
developed multifocal pulmonary bronchiolo-alveolar adenocarcin-
omas originating from the alveolar epithelium. Littermates of the
SP-C/IgEGF transgenic mouse line 6.2 showed no bronchiolo-
alveolar adenocarcinomas, but they developed hyperplasias
derived from the alveolar epithelium. The observed phenotypes of
all founder mice and their offspring are summarized in Table 1.
Transgene expression could be detected in the lung from all shown
founder animals and the copy number of the transgene c-myc was
1–2 copies for the established transgenic lines SPC/myc 8.2 
and 13.0 and 2–3 copies for the founder animals SPC/myc 3.2 and
SPC/myc 13.0 (Table 1). The following work is focused on the
transgenic mouse lines SP-C/myc 8.2 and SP-C/IgEGF 6.2. 
Expression of the SP-C/myc and SP-C/IgEGF transgene 
RNA was isolated from tissues of littermates of the transgenic
mouse lines SP-C/myc 8.2 and SP-C/IgEGF 6.2 and subjected 
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detected only in the lung of both transgenic mice (Figure 1C, D)
and not in any other tissue including salivary gland, liver, pancreas
and ovary (not shown). Non-transgenic mice showed no signal in
the lung for both transgenes, respectively (Figure 1C, D). 
Development of hyperplasias in SP-C/IgEGF
transgenics and development of bronchiolo-alveolar
adenocarcinomas in SP-C/myc transgenics 
Expression of the SP-C/IgEGF transgene induced the develop-
ment of alveolar hyperplasias in the alveolar epithelium (Figure 2A)
when compared to non-transgenic mice (Figure 2B). Alveolar
hyperplasias in analysed SPC/IgEGF individuals occurred at the
average of 19 months. In SP-C/myc transgenics different stages
of tumour development in the alveoli were frequently observed.
Large bronchiolo-alveolar adenocarcinoma developed only in the
lung of SP-C/myc transgenics. Early stages of tumour develop-
ment were characterized by multifocal hyperplasias originating
in the alveolar epithelium (Figure 2C). Adenomas, which devel-
oped in the alveolar septae were observed in lung sections of SP-
C/myc transgenics at the age of 6–7 months (Figure 2D).
Advanced stages of carcinogenesis consisted of multifocal bron-
chiolo-alveolar adenocarcinomas (Figure 2E) were detected in
SP-C/myc transgenics at the average age of 14.25 months,
whereas the bronchiolar epithelium was not affected. Figure 2F
demonstrates a lung of a non-transgenic and of a SP-C/myc trans-
genic mouse, both of 14 months of age. One lobe of the lungs
was completely transformed to a bronchiolo-alveolar adenocarci-
noma. 
Generation of homozygous SP-C/myc transgenics and
hemizygous double transgenic mice expressing c-myc
and IgEGF 
The medial survival times of hemizygous SP-C/myc transgenics is
14.25 months (Table 2), whereas the medial age of death of
homozygous SP-C/myc transgenic is 9.2 months (Table 2). At the
age of 14.25 months and 9.2 months respectively, 75% of all
hemizygous and 80% of homozygous mice were diagnosed with
bronchiolo-alveolar adenocarcinomas transforming both lung
lobes (Table 2 and Figure 2F). These findings suggest that a gene
dosage effect of c-myc expression contributed to the accelerated
tumor development as compared to hemizygous transgenics.
Hemizygous and homozygous mice were distinguished by
Southern analysis (Figure 3). A summary of homozygous and
hemizygous SP-C/myc transgenics, their phenotype, and their life
expectancies are shown in Table 2. These results demonstrated that
c-myc overexpression was causally involved in bronchiolo-
alveolar adenocarcinoma formation. A gene dosage effect was also
observed in another transgenic mouse, who expressed SV40 Tag
under the control of the fetal globin promoter. In this transgenic
mouse strain prostate tumours were induced in 75% of the male
hemizygous for the transgene but in 100% of all male homozygous
mice (Perez-Stable et al, 1997). 
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Figure 1 Fusion genes SP-C/myc (A) and SP-C/IgEGF (B) for generation 
of transgenic mice. Northern analysis of total RNA from lung tissue of 
SP-C/myc (C) and SP-C/IgEGF (D) transgenic mice. The 2700 bp Sa/I/EcoRI
c-myc and the 360 bp Sa/I IgEGF fragments were used as [32P] labelled
probes for hybridization in Northern analysis.
Table 1 Summary of examined SP-C/myc and SP-C/IgEGF transgenic founder mice, their offspring and their phenotypes
Founder transgenic line Transgene Phenotypes in the lung
[No. of generations] expression (lung)/
copy number of
the transgene
SP-C/myc no +/2–3 Multifocal bronchiolo-alveolar adenomas and bronchiolo-alveolar adenocarcinomas
3.2
SP-C/myc no +/2–3 Hyperplasias in alveolar epithelium
4.2
SP/C/myc yes +/1–2 Multifocal bronchiolo-alveolar adenomas and brochiolo-alveolar adenocarcinomas
8.2 [20]
SP-C/myc yes +/1–2 Multifocal brochiolo-alveolar adenomas and bronchiolo-alveolar adenocarcinomas
13.0 [7]
SP-c/myc no +/2–3 Hyperplasias in alveolar epithelium
16.2
SP-C/IgEGF yes +/n.d Hyperplasias in alveolar epithelium
6.2 [20]To generate hemizygous double transgenics expressing c-myc
and IgEGF, offspring of transgenic mouse lines SP-C/myc 8.2 and
SP-C/IgEGF 6.2 were cross-bred. Littermates were analysed for
the presence of both transgenes by Southern analyses. The life
expectancy of SP-C/myc/IgEGF double transgenic individuals
analysed so far was 9 months, which was clearly reduced
compared to the medial survival times of hemizygous SP-C/myc or
SP-C/IgEGF transgenics, i.e. 14.25 and 19 months, respectively
(Table 2). 100% of examined SP-C/myc/IgEGF double transgenics
were diagnosed with bronchiolo-alveolar adenocarcinomas (Table
2).  From these results we conclude, that c-myc and IgEGF cooper-
ated during lung tumour formation. Histological analysis
confirmed that lung tumours in SP-C/myc/IgEGF double trans-
genics originated from AT-II cells and thus were classified as bron-
chiolo-alveolar adenocarcinomas (not shown). The number of
lesions in the 4 examined double transgenics is macroscopically
lower but the lesion size is enlarged in comparison to SPC/myc
transgenics at the age of 9 months. We speculate that additional
randomly occurring genetic changes in each lesion have to take
place for tumour induction. 
Gene expression in lung tumours of transgenic mice 
Expression of one transgene in a target tissue is usually not suffi-
cient for tumour development. Therefore we analysed tumours 
for abnormal expression of selected proto-oncogenes. We also
checked expression patterns of genes which are known to be
typically expressed in AT-II cells, in order to obtain information
about the extent of dedifferentiation of the tumour cells as
compared with AT-II cells from which they were derived. For
this purpose we used the reverse Northern slot blot hybridization
technique. Lungs of non-transgenic CD2F1 littermates (14
months old), from tumour nodules of SP-C/myc transgenics (14
months old) and from tumour nodules of SP-C/myc/IgEGF
double transgenics (9 months old) were investigated. The inten-
sity of mRNA expression of three surfactant proteins, which are
known to be expressed in AT-II cells, differed moderately among
the analysed tissues in comparison to those of non-transgenic
littermates (Figure 4). The expression levels also differed among
tissues from mice expressing c-myc or both, c-myc and IgEGF,
which may indicate various stages of dedifferentiation of the
lung tumour tissue. 
To analyse the expression levels of genes involved in regulating
cell proliferation we analysed the expression of selected cell
cycle regulating genes including cyclin D1, cdc2 and c-jun. The
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Figure 2 Histology of a lung of a non transgenic and a SP-C/IgEGF
transgenic mouse. (A) The lung of a SP-C/IgEGF transgenic mouse was
showing multifocal hyperplasias of the alveolar epithelium which was
indicated by the increased cellularity in the alveoli. (B) A normal lung with thin
alveolar septae in a non transgenic mouse. (A, B: bar = 20 mm).
Several stages of tumor development frequently observed in the lungs of the
transgenic mouse line SP-C/myc 8.2. (C), alveolar hyperplasia: The alveoli
exhibit a hyperplastic epithelium consisting of cuboidal cells lining the
alveolar septa and ducts. (D), bronchiolo-alveolar adenoma: It is indicated by
a circumscript neoplasia forming papillary patterns (right of the picture). The
surrounding lung tissue is compressed by the tumor growth (left). (E),
bronchiolo-alveolar adenocarcinoma: Cells invading the alveoli exhibit a
papillary growth pattern, whereby the bronchiolus (arrows) is not affected.
Due to the invasion of tumor cells in the adjacent lung tissue the tumors
appear poorly circumscribed. Note the multifocal origin of the bronchiolo-
alveolar adenocarcinoma. Progressive growth resulting finally in solitary
tumor masses replacing the lung parenchyma. (C–E: bar = 200 mm). (F) Lung
of a SP-C/myc transgenic and of a non transgenic mouse. The lung of the
SP-C/myc transgenic mouse developed bronchiolo-alveolar adenocarcinoma
replacing most of the normal lung tissue (arrow).
Table 2 Summary of analysed homozygous and hemizygous mice and their pheotypes; (+/0), hemizygous mice; (+/+),
homozygous mice
Transgenic Genotype Pathology % of animals with each Medical age of
mouse line kind of pathology [No. Death [mean values
of analysed animals] +/–SEM]
SP-C/myc 8.2 +/0 bronchiolo-alveolar 75% 14.25 +/–1.07 months
adenocarcinomas [14]
SP-C/IgEGF +/0 Hyperplasia 66.7% 19 +/–0.41 months
[3]
SP-C/myc 8.2 +/+ bronchiolo-alveolar 80% 9.2 +/–1.07 months
adenocarcinomas [5]
SP-C-myc/IgEGF +/0; brochiolo-alveolar 100% 9.0 +/–1.29 months
+/0 adenocarcinomas [4]expression of these genes was distinctly increased in tumour
nodules of SP-C/myc/IgEGF double transgenics, but not in
tumours of SP-C/myc transgenics or in normal lung tissue (Figure
4). These preliminary results indicated increasing deregulation of
the cell cycle at various stages of lung tumour development in the
SP-C/myc/IgEGF double transgenics. It can be speculated that the
deregulation of cell cycle regulating genes might be the reason for
the decreased medial survival times in these mice (Figure 4). 
DISCUSSION 
Constitutive overexpression of c-myc under the transcriptional
control of the SP-C promoter is frequently associated with
the development of bronchiolo-alveolar adenocarcinomas,
adenomas or hyperplasias in transgenic mice. Hemizygous
SPC/myc and SPC/IgEGF and homozygous SPC/myc transgenic
mice examined in this study had a life span of between 9 and
14.25 months. Not all analysed transgenic mice developed bron-
chiolo-alveolar adenocarcinomas. We speculate that additional
genetic changes have to occur for tumour induction, e.g. knock
out of tumour suppressor and/or activation of proto-oncogenes.
These events occur randomly and may explain that not all
offspring develop tumours. However, death inducing sponta-
neous bronchiolo-alveolar adenocarcinomas are uncommon at
this age, but it should considered, that spontaneous lung tumours
are not a rare event in mice. Reported data are related to the age
24 month, are not specified for bronchiolo-alveolar entities and
are not available for the hybrid strain CD2F1 (compare overview
in Rittinghausen et al, 1997). It should be emphasized, that non-
transgenic control mice of the breed and age used for transgenic
studies, did not display any lung tumours. Therefore, it is
evident, that the bronchiolo-alveolar neoplasias or hyperplasias
were indeed caused by the overexpression of the c-myc trans-
gene. The role of c-myc overexpression as a first step in the
process of tumour formation was further confirmed by the gene
dosage effect observed in homozygous transgenics, which
showed accelerated tumour development in the lung. These find-
ings support the hypothesis that this gene is causally involved in
the development of human alveolar lung bronchiolo-alveolar
adenocarcinomas, where overexpression of c-myc is frequently
observed (Broers et al, 1993; Lorenz et al, 1994). 
Overexpression of IgEGF under the control of the SP-C
promoter led to the formation of hyperplasias of the alveolar
epithelium in the lung of transgenic mice, whereas overexpres-
sion of TGFa in the lung of transgenic mice has been shown to
induce enlarged parenchymal airspace and pulmonary fibrosis
(Hardie et al, 1997). The induction of different phenotypes
by IgEGF and TGFa might be due to the fact that EGF – but not
TGFa – binds to other receptor subunits of the EGF receptor
family; e.g. erbB2, 3 and/or 4 (Alimandi et al, 1997; Wang et al,
1998). A similar cooperation of c-myc and IgEGF, which led
to accelerated bronchiolo- alveolar adenocarcinomas formation
in SP-C/myc/IgEGF double transgenics was also demonstrated
for hepatocarcinogenesis in transgenic mouse lines, which
overexpress these oncogenes in hepatocytes (Tönjes et al, 1995). 
First results indicate that other genes may be involved in the
accelerated growth of tumors in SP-C/myc/IgEGF double trans-
genics (Figure 4). The expression level of cyclin D1 was shown 
to be strongly increased in tumour nodules of SP-C/myc/IgEGF
double transgenic mice but not in lungs of non-transgenics or 
SP-C/myc transgenics. It is known that EGF induces cyclin D1
Role of c-myc and EGF in lung adenocarcinoma formation 817
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Figure 3 Southern analysis of homozygous and hemizygous SP-C/myc 8.2
transgenic mice. DNA, isolated from biopsied tails of SP-C/myc transgenic
mice, was digested with BamHI. A diagnostic 3.5 kb transgene specific
fragment was detected in the DNA of all transgenic mice but not in non
transgenic mice. An additional 6.0 kb BamHI fragment represents the
endogenous c-myc DNA fragment, which was found in transgenic and non
transgenic mice. Homozygous transgenic mice are characterized by a
stronger signal of the transgene specific c-myc DNA fragment in comparison
to the endogenous c-myc DNA fragment. myc/0, hemizygous SP-C/myc
transgenic mouse; myc/myc, homozygous SP-C/myc transgenic mouse; 0/0,
non transgenic mouse
pBR322
actin
SP-A
SP-B
SP-C
cycD1
cdc2
c-jun
CD2F1
lung
SP-C/myc
lung tumour
SP-C/myc/IgEGF
lung tumour
Figure 4 Gene expression profiles in the lungs of non transgenic littermates,
in SP-C/myc transgenic and in SP-C/myc/IgEGF double transgenic mice. A
subset of plasmids containing c-DNA sequences of the indicated genes were
denatured and immobilized on a nylon membrane. The filters were hybridized
with a [32P]-labeled cDNA, which was generated by reverse transcription of
poly A+ mRNA from lung tissue of a non transgenic littermate, from a tumor
nodule of the lung of a SP-C/myc transgenic and from a tumor nodule of the
lung of a SP-C/myc/IgEGF double transgenic mouse. cycDI, cyclin DIexpression (Ravitz et al, 1996; Ramljak et al, 1998), which is one
of the most frequently overexpressed oncogenes in human
bronchiolo-alveolar adenocarcinomas (Marchetti et al, 1998). 
Also, cdc2 and c-jun were overexpressed in lung tumours of 
SP-C/myc/IgEGF double transgenics. cdc2 is an important cell
cycle controlling gene, which binds to and activates cyclin B1.
Upregulation of c-jun was also observed in human cell lines
established from NSCLC when stimulated by growth factors
(Szabo et al, 1996). These observations indicate that the tumours
in the transgenic mice are excellent models for human lung
adenocarcinomas, which will be useful for understanding the
molecular basis for the development of human lung cancer.
Future experiments, involving gene expression profiles of devel-
oping tumours, that include a broader spectrum of tumour
suppressor and oncogenes, will provide a more detailed view,
which genes become involved during tumour progression 
in developing lung carcinomas in SP-C/myc as well as in 
SP-C/myc/IgEGF double transgenic mice. 
The surfactant proteins SP-A, SP-B and SP-C were expressed
moderately reduced or at similar levels in tumours of SP-C/myc
and SP-C/myc/IgEGF transgenics as compared to lungs of non-
transgenics indicating that bronchiolo-alveolar adenocarcinomas
were derived from AT-II cells. Expression of SP-C was also
shown to occur in human bronchiolo-alveolar adenocarcinomas
(Linnoila et al, 1992) suggesting similarities between human
bronchiolo-alveolar adenocarcinomas and the homologous
tumour type in SP-C/myc transgenics. In summary we present a
new model for bronchiolo-alveolar adenocarcinomas, which will
be useful to address several questions about lung tumour 
formation. 
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